Elena Gobartt, Medical Director for Specialized Care at Boehringer Ingelheim Spain.
One in five patients interstitial lung disease can develop a Progressive pulmonary fibrosis (PPF), which affects the patient’s quality of life and is associated with a higher mortality rate. Several experts spoke about this during the “Clinical Advances in Pulmonary Fibrosis” symposium held in 55th Congress of the Spanish Society of Pulmonology and Thoracic Surgery (separate)from 2 to 4 June in Pamplona, with the aim of continuing the progress in early diagnosis The best approach to this disease.
The Diffuse interstitial lung disease (DILD) Is a diverse group of more than 200 heterogeneous lung diseases, among which idiopathic pulmonary fibrosis (IPF) It is the most common. When a person has IPF, a rare, advanced disease, the lungs become scarred and stiff, making it difficult for oxygen to get to the blood and causing shortness of breath. IPF is the only ILD that always has an IPF, but other types of ILD can also show it in some cases, thus presenting a path and outlook similar to those of IPF.
seminar manager, Claudia ValenzuelaPulmonologist, Head of the ILD Unit of the Respiratory Service at La Princesa University Hospital (Madrid) and Coordinator of the ILD Separate District, explains: “Progressive pulmonary fibrosis is not an entity in itself, but a behavior found in IPF – the prototype of progressive fibrous lung disease. – Since it is diagnosed it can also occur in other fibrous lung diseases. PPF can appear in other ILDs that are not IPF And that, at some point in the course of the disease, they may present this progressive fibrotic behavior.
“In 2018, a group of experts described this behavior, in some chronic disease patients, with similar characteristics to IPF, and the first prevalence studies in different groups were published. Last May, some Upgrade guides in IPF. This includes a section with all the guides available so far It aims to standardize terminology And we’re talking about progressive pulmonary fibrosis.” As the specialist notes, these guidelines “establish clinical, functional, and radiological criteria to be able to identify this behavior when it occurs in ILD diseases that are not IPF.”
PPF is characterized by diffuse, sustained and irreversible fibrosis that exacerbates respiratory symptoms and reduces lung function, thus slowing disease progression is essential for quality of life and the patient’s prognosis, because it is associated with a high mortality rate. In addition to the functional impact, patients with PPF may experience emotional disturbances, such as depression.
during the seminar, Athol Waleswho specializes in metastatic lung diseases at Royal Brompton Hospital (UK), reviews how the concept of PPF arose and reviews the evidence for its current definition with Marie MolinaHead of the Pulmonology Research Group at the University Hospital Belvetigue (Barcelona) and Coordinator of the Functional Unit of the Lungs Interstitial Unit (UFIP), who reviewed the recently published update of the International Manual ATS/ERS/JRS/ALAT.
Boehringer opens the door to more possibilities
for this part, Luca RicheldyMD, director of the Department of Pulmonary Medicine at Gemelli University Hospital (Italy), spoke about the safety and efficacy of BI1015550 in Boehringer Ingelheim’s latest clinical trial on IPF patients, where he was the study’s lead investigator. This molecule is an oral phosphodiesterase 4B (PDE4B) inhibitor which, currently under study, could have The ability to treat both pulmonary fibrosis and associated infections For progressive interstitial fibrotic lung disease.
Data from a phase II clinical trial obtained at 12 weeks showed a reduction in the rate of deterioration of lung function in patients with chronic pulmonary fibrosis, both in those not receiving anti-fibrotic therapy and in those receiving it. After these results, Boehringer Ingelheim a . will start Phase III clinical trial program With the ambition to make this drug available to patients as quickly as possible.
In February 2022, the US Food and Drug Administration (FDA) granted a classification of innovative treatment To this new, tested drug, which is not currently approved in any country for any indication.
Separate research grants for young talents
During the conference, Boehringer Ingelheim awarded three research grants to projects submitted by members of the ILD Emerging Group (Geepid), established within the separate ILD region in order to: encourage research among its younger members. The aim of this aid is, 5000 Euro Each one, is to support research projects submitted by scholarship recipients regarding diffuse interstitial lung disease.
The projects selected were Candela Serapulmonologist at Hospital de la Santa Cruz y Sant Pau (Barcelona), on “Characterization of cases of pulmonary toxicity secondary to immunotherapy”; Oswaldo Antonio Caguana Velez, pulmonologist at Hospital del Mar (Barcelona), on “The effect of oxygen therapy on exertion on the activity of patients with chronic unsaturated lung diseases on exertion”; and one of Elisa Martinez Besteropulmonologist at Hospital de la Princesa (Madrid), on “Mucosal fibroblastosis: epidemiology, diagnostic characterization, diagnosis and management”.
Elena JubartDirector of Medical Affairs for Specialized Care in Boehringer Ingelheim Spain, notes the company’s commitment to difficult-to-diagnose lung diseases, noting that: “At Boehringer Ingelheim, we have long path In pulmonary fibrosis research, and with this experimental new drug, which has been shown to slow the deterioration of lung function in patients with pulmonary fibrosis, we have Ambition to continue adding value through innovation.
“In line with our commitment to the dissemination of interstitial lung disease and independent research, we offered three scholarships to members of the emerging Geepid group at the separate conference, thus sharing with top pulmonologists and young talent the need for Keep finding solutions for these diseases. If we all join in the effort, we will make more progress for the future of pulmonary fibrosis.”
Boehringer Ingelheim has been working together with scientific societies such as separate societies and patients for years to promote Awareness campaigns which improve knowledge of pulmonary fibrosis; Promote valuable patient assistance programs and enhance cross-sectional training of key specialists in the pulmonary fibrosis approach. In fact, the site of progression in pulmonary fibrosis provides Scientific Updates, Guides & Courses To help identify and manage pulmonary fibrosis early in many diseases, including progressive pulmonary fibrosis.
Although it may contain statements, statements, or notes from health institutions or professionals, the information in medical writing is edited and prepared by journalists. We recommend the reader to consult a health professional for any health-related questions.